CEO
Functional Fluidics
Wayne State University School of Medicine
Detroit, Michigan, United States
Dr. Hines has spent over 20 years investigating the mechanisms regulating microvascular blood flow in sickle cell disease, including sickle erythrocyte adhesion, leukocyte rolling, and platelet function and is the author of numerous peer reviewed publications and abstracts in this field. As a practicing pediatric intensivist (cardiac and general), his passion for translating basic science research to the bedside is fueled by the clinical problems he encounters in the ICU. Equally important to his academic achievements, he is internationally recognized for his efforts to develop and validate a gold standard for the assessment of red blood cell health in clinical practice. Red blood cell-modifying therapies have been under development for many years, and we are now experiencing a surge of FDA approvals. Dr. Hines has led the effort to translate basic science into standardized clinical tests that can predict outcomes in people with sickle cell disease, and monitor patient response to these first in class red blood cell modifying therapies. By leveraging red blood cell function biomarkers to make red blood cell health a goal of therapy, Dr. Hines believes providers can keep individuals with sickle cell disease healthy as opposed to focusing healthcare resources on managing crises. He founded Functional Fluidics in 2014 to further develop specialized blood-based bioassays with the potential to identify patients at risk for blood flow abnormalities or hemolysis, and facilitate early intervention. Functional Fluidics has provided red blood cell health assessment for some of the largest sickle cell centers in the United States, in addition to companies developing red blood cell-modifying therapies. Dr. Hines is leading an effort to validate the role of red blood cell function in congenital heart disease, prediction of preterm births and low birth weight, diabetic vasculopathy, assessment of storage lesions in blood banked RBCs, assessment of RBC damage by ECMO and artificial hearts, and aerobic capacity in high performance athletes. In recognition of this work, Dr. Hines was selected as an Aspen Health Innovation Fellowship within the Aspen Global Leadership Network and recipient of the Crain’s Detroit Business 40 Under 40 award, an honor rarely given to physician leaders. He completed both his fellowship in critical care medicine and pediatrics residency at the Children’s Hospital of Philadelphia. He received his M.D. degree and Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill, and Bachelor of Science in Chemistry from Hampton University.
Disclosure information not submitted.
Biomarker Response to Administration of Adakveo in a “Real World” Clinical Setting
Sunday, June 18, 2023
3:45 PM – 4:00 PM East Coast USA Time